Lupus (SLE) trials in Peru
8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- No phaseTaking peopleDeciphering the Genetic Architecture of Autoimmune Diseases
- Where
- Lima
- Age
- 18 years to 115 years
- People
- 300 worldwide
- Run by
- National Human Genome Research Institute (NHGRI)
See details and how to joinNCT06948110 - Phase 2Taking peopleA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Where
- Lima, San Isidro
- Age
- 5 years to 17 years
- People
- 40 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- Arequipa, San Juan de Lurigancho, Surco
- Age
- 16 years and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - Phase 1Taking peopleA Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
- Where
- Lima
- Age
- 18 years to 75 years
- People
- 21 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07363590 · EU 2025-523412-36-00 - Phase 2Taking peopleA Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
- Where
- Lima
- Age
- 5 years to 17 years
- People
- 24 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07630714 · EU 2025-524578-41-00 - Phase 3Enrolling by invitationA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- Lima
- Age
- 16 years and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - Phase 3Enrolling by invitationA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Lima
- Age
- 18 years and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00 - Phase 3Enrolling by invitationLong-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
- Where
- Jesus Maria, Lima, San Borja, San Isidro, San Juan de Lurigancho, Santiago de Surco
- Age
- 18 years to 75 years
- People
- 680 worldwide
- Run by
- Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00